InterCept Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (60)

Latest Posts

About This Stock More About This Stock
Intercept Downgraded To Sell From Neutral At Goldman Sachs
Article By: The Fly
Friday, August 20, 2021 7:12 AM EST
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $10, down from $17, implying a 30% downside.
In this article: ICPT
Read
Hidden Gem Report: Intercept Pharma Ready To Explode
Article By: Gareth Soloway
Tuesday, May 18, 2021 4:13 PM EST
This biotech company is flying under the radar and could see easily 100% upside in the near-term based on both fundamental and technical signals.
In this article: ICPT
Read
Intercept Downgraded To Sell From Neutral At H.C. Wainwright
Article By: The Fly
Tuesday, February 23, 2021 8:22 AM EST
H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $25, down from $46, after the company disclosed that its Chief Medical Officer Jason Campagna has decided to resign effective March 5.
In this article: ICPT
Read
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich
Friday, January 26, 2018 6:44 PM EST
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
Oppenheimer Downgrades Intercept Despite Two-Day Share Collapse
Article By: The Fly
Friday, September 22, 2017 2:23 PM EST
Oppenheimer analyst Jay Olson downgraded this afternoon shares of Intercept Pharmaceuticals to Perform from Outperform.
In this article: ICPT
Read

Latest Tweets for $ICPT

No tweets yet!